Albert Boerla wins Genesis Prize 2022

Category : Awards Published on: January 22 2022

Share on facebook

The global pharmaceutical giant Pfizer Inc.’s Chairman and Chief Executive, Albert Bourla, has been awarded with the prestigious Genesis Prize 2022 on January 19, 2022.
He has been awarded for his efforts in leading the development of a COVID-19 vaccine (Pfizer–BioNTech COVID-19 vaccine).
The cash prize of this award is $1 million.
The annual prize is awarded to Jewish people who have achieved significant professional success, in recognition of their accomplishments, contributions to humanity, and commitment to Jewish values and/or to the State of Israel.
It is widely referred to as the “Jewish Nobel Prize”.

India and France are negotiating a €300 million deal to procure SCALP cruise missiles after their successful combat use in Operation Sindoor.
Read More....
India improved to 91st rank in the Corruption Perceptions Index 2025, though global corruption levels remain high.
Read More....
French President Emmanuel Macron will visit India to strengthen strategic cooperation under the Horizon 2047 roadmap.
Read More....
17-year-old Aditya Pandya became India’s youngest analog astronaut after completing a lunar simulation mission.
Read More....
Scientists discovered a new dragonfly species, Lyriothemis keralensis, endemic to Kerala.
Read More....
India has been named Country of the Year at BIOFACH 2026 in Germany, highlighting its rising global leadership in organic agriculture and exports.
Read More....
A new frog species discovered in Peru’s cloud forests may already face extinction due to habitat loss.
Read More....
Manu Bhaker won silver in the 25m pistol event after a shoot-off at the Asian Championship.
Read More....
International Day of Women and Girls in Science is observed on 11 February to promote equal participation of women in STEM and build inclusive futures.
Read More....
Thanya Nathan is set to become Kerala’s first visually challenged woman judge after topping the civil judge exam list.
Read More....